Menu
← Oncology Approval Tracker
FDA DECISION ·
Sarclisa Escena + VRd
subcutaneous isatuximab-irfc with bortezomib, lenalidomide and dexamethasone · Sanofi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplant.
LAMPGEN ANALYSIS
Why it matters
The new formulation also applies to a front-line regimen in transplant-ineligible patients. The IsaSocut evidence is a separate single-arm study from the randomized route comparison in relapsed disease.
What research teams should watch
Document transplant eligibility and align each drug in the regimen with its administration schedule. The route change should be reflected in pharmacy and nursing workflows.
PRIMARY RECORDS